DHR
HEALTHCAREDanaher Corporation
Danaher Corporation (DHR) is currently priced at $178.19, reflecting a slight increase of 0.58% today. The technical indicators suggest a neutral sentiment, with a HOLD signal at a confidence level of 45%. The Relative Strength Index (RSI) stands at 48.4, indicating that the stock is neither overbought nor oversold. The stock is trading below its short-term simple moving average (SMA20) of $179.91 and its SMA50 of $179.25, while significantly lower than the SMA200 of $204.12. The MACD value of 0.55, with a signal line at 0.89 and a histogram of -0.34, further reinforces the lack of strong momentum in either direction.
From a fundamental perspective, Danaher exhibits strong growth metrics, with an impressive revenue growth of 290.3% year-over-year and a quarter-over-quarter growth of 3.7%. The earnings per share (EPS) of $5.16 reflects a robust quarterly growth of 9.8%. However, the company’s high P/E ratio of 34.3, compared to a forward P/E of 21.0, suggests that the stock may be overvalued relative to its growth potential. The gross margin of 6093.3% and operating margin of 2090.9% indicate exceptional profitability, yet the return on equity (ROE) of 7.1% suggests that capital efficiency could improve. Analyst sentiment remains positive, with a consensus rating of BUY (4 strong buy, 19 buy, 2 hold) and a target price of $242.35, indicating substantial upside potential from the current price.
Looking ahead, Danaher will report its next earnings on July 20, 2026, before the market opens, which is a crucial upcoming catalyst. Investors should pay close attention to this earnings report, particularly for any indications of margin compression or changes in revenue growth trends. The recent news about the scheduled earnings conference call and potential dividends could also influence investor sentiment. As the earnings date approaches, market participants will likely focus on whether Danaher can maintain its growth trajectory amidst a challenging economic environment.
What's Moving DHR Today?
No stock-specific AI insight has been generated for DHR yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$179.63
Fundamentals
Trading
DHR News
137 articles- 1 Profitable Stock with Promising Prospects and 2 That UnderwhelmYahoo Finance·Jun 23, 2026
- Is AMETEK Stock Just More Market Exposure?Trefis·Jun 22, 2026
- Danaher Schedules Second Quarter 2026 Earnings Conference CallTradingView·Jun 22, 2026
- Danaher plans July 21 earnings call, slide deck at 6 a.m. ETStock Titan·Jun 22, 2026
- Why You Might Be Interested In Danaher Corporation (NYSE:DHR) For Its Upcoming DividendSimply Wall Street·Jun 22, 2026
- Revvity focuses on biologics software strategy, shares trade quietly on the NYSEAD HOC NEWS·Jun 22, 2026
- Masimo Receives FDA 510(k) Clearance for AI-Enabled Opioid-Induced Respiratory Depression (OIRD) Detection on Radius VSM® to Help Identify Respiratory Risk SoonerYahoo Finance·Jun 22, 2026
- AMETEK Stock - Weekly review and sector comparison after quiet news flowAD HOC NEWS·Jun 19, 2026
- Global Automated Liquid Handling Systems Market Size/Share Worth USD 6.9 Billion by 2035 at a 9.8% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)GlobeNewswire Inc.·Jun 19, 2026
- Lodi's largest private employer expands with fifth buildingThe Business Journals·Jun 18, 2026
- Medtech M&A maintains momentum following decade-high 2025: PwCMedtechdive·Jun 17, 2026
- Analysts' Top S&P 500 Stocks to Buy NowKiplinger·Jun 16, 2026
- Why This Once-in-a-Decade Selloff Makes One Waste Management Company a Forever Stock24/7 Wall St.·Jun 16, 2026
- IDBS and Alchemi partner to accelerate biopharma regulatory filings with compliant AI agentsYahoo Finance·Jun 16, 2026
- Danaher’s Cepheid Ebola Tests Highlight Diagnostics Role In Global CrisesYahoo Finance·Jun 15, 2026
- Masimo CEO stepping down following acquisition by DanaherModern Healthcare·Jun 15, 2026
- Danaher Corporation’s (DHR) Recovery Fell Short of Investor ExpectationsYahoo Finance UK·Jun 15, 2026
- Weak Subscription Revenue Growth Pressured Gartner (IT) in Q1Insider Monkey·Jun 15, 2026
- 3 of Wall Street’s Favorite Stocks with Questionable FundamentalsYahoo Finance·Jun 15, 2026
- Jim Cramer on Fortive: “It’s Nothing Special, Frankly”Insider Monkey·Jun 15, 2026
- Piper Sandler Begins Coverage of Danaher (DHR) While Waiting for New Growth CatalystsYahoo Finance UK·Jun 15, 2026
- Billionaire Larry Robbins’ 10 Dividend Stock PicksInsider Monkey·Jun 14, 2026
- Waters Corporation Stock (US9418481035): Fundamentals and valuation under the microscopeAD HOC NEWS·Jun 14, 2026
- Danaher Deepens Diagnostics Reach As Masimo Deal Reshapes Healthcare FocusYahoo Finance·Jun 14, 2026
- Fortive Corporation $FTV Stake Lowered by Clean Energy Transition LLPMarketBeat·Jun 14, 2026
- Masimo (MASI) director equity cashed out at $180 per share in Danaher mergerStock Titan·Jun 12, 2026
- Masimo (MASI) GC reports RSU disposals as Danaher merger converts awardsStock Titan·Jun 12, 2026
- Masimo (MASI) CMO disposes RSUs, options as Danaher merger closesStock Titan·Jun 12, 2026
- Danaher Completes Masimo Deal And Broadens Patient Monitoring Growth StorySimply Wall Street·Jun 12, 2026
- 3 Reasons to Avoid DHR and 1 Stock to Buy InsteadYahoo Finance·Jun 12, 2026
- Cepheid Delivers Xpert® Hemorrhagic Fever Panel Tests to Africa to Address Diagnostic Gaps in Ebola Bundibugyo OutbreakYahoo Finance·Jun 12, 2026
- Danaher Boosts Product Portfolio With the Acquisition of MasimoYahoo Finance·Jun 12, 2026
- Implied Volatility Surging for Danaher Stock OptionsYahoo Finance·Jun 12, 2026
- 1 Unstoppable Healthcare Cash Cow to Buy Hand Over Fist and Hold for 25 Years247 Wall St·Jun 11, 2026
- Strong Performance Continues at DHR's Biotechnology Unit: What's Next?Yahoo Finance·Jun 11, 2026
Price Data
52-Week Range
$179.63
Fundamentals
Trading
About Danaher Corporation
Danaher Corporation is an American globally diversified conglomerate with its headquarters in Washington, D.C.. The company designs, manufactures, and markets professional, medical, industrial, and commercial products and services. The company's 3 platforms are Life Sciences, Diagnostics, and Environmental & Applied Solutions.